- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The great debate at “Immunotherapy Bridge 2018”, Naples, November 29th, 2018 ; volume:7 ; number:1 ; day:15 ; month:8 ; year:2019 ; pages:1-12 ; date:12.2019
Journal for ImmunoTherapy of Cancer ; 7, Heft 1 (15.8.2019), 1-12, 12.2019
- Creator
-
Ascierto, Paolo A.
Butterfield, Lisa H.
Demaria, Sandra
Ferris, Robert L.
Freeman, Gordon J.
Lo, Roger S.
Mantovani, Alberto
Nathan, Paul
Hamid, Omid
Politi, Katerina
Puzanov, Igor
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40425-019-0683-0
- URN
-
urn:nbn:de:101:1-2020010113061691766048
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:04 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ascierto, Paolo A.
- Butterfield, Lisa H.
- Demaria, Sandra
- Ferris, Robert L.
- Freeman, Gordon J.
- Lo, Roger S.
- Mantovani, Alberto
- Nathan, Paul
- Hamid, Omid
- Politi, Katerina
- Puzanov, Igor
- SpringerLink (Online service)
Other Objects (12)
The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Melanoma: the role of surgery in the era of new therapies
What have we learned from cancer immunotherapy in the last 3 years?
Combination therapy: the next opportunity and challenge of medicine
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy)
The Great Debate at “Melanoma Bridge”, Naples, December 7th, 2019
Melanoma: A model for testing new agents in combination therapies
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy)
The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Melanoma: the role of surgery in the era of new therapies
What have we learned from cancer immunotherapy in the last 3 years?
Combination therapy: the next opportunity and challenge of medicine
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy)
The Great Debate at “Melanoma Bridge”, Naples, December 7th, 2019
Melanoma: A model for testing new agents in combination therapies
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy)
The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Melanoma: the role of surgery in the era of new therapies
What have we learned from cancer immunotherapy in the last 3 years?
Combination therapy: the next opportunity and challenge of medicine
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy)
The Great Debate at “Melanoma Bridge”, Naples, December 7th, 2019
Melanoma: A model for testing new agents in combination therapies
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application